Description
Inconsistent practices and information about the use of low-dose methotrexate for inflammatory diseases results in unfounded patient and health professional concerns, which can influence therapy decisions and adherence.
CATAG developed a Position Statement relating to best practice use of low-dose methotrexate in hospitals for DTCs and clinicians.
This was presented as a lightning talk at the National Medicines Symposium 2021.
This work was funded by the Australian Government Department of Health through the Value in Prescribing – bDMARDs Program Grant.